The investment of 19,4 million USD was made through Caladrius Biosciences, a US subsidiary. PCT Inc.’s cell culture processing facilities are compliant with GMP standards. Hitachi plans to enter contract manufacturing of cell therapeutical products in Japan by around 2018 and expand further in Asia, the USA and Europe.

Hitachi Chemical news release, March 15, 2016